OVERVIEW

17th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® is organized by Physicians' Education Resource, LLC (PER). This CME webinar will be held on Feb 06, 2021.

Accreditation:
Physicians’ Education Resource®, LLC assigns this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians will be able to earn the credit commensurate based on the extent of their participation in the activity.

Physicians’ Education Resource®, is recommended by the California Board of Registered Nursing, Provider #16669, for 6.5 Contact Hours.

Overview:
The 17th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® is a single-day educational conference intended to review prevailing and emerging treatments in melanoma, basal cell carcinoma, squamous cell carcinoma, and other skin-related cancers. This engaging program, with insights from world-renowned experts, will bring you up-to-date on the emerging standards of care in melanoma and other cutaneous malignancies.

The fast-paced and interactive nature of this symposium will present concise yet thorough updates for physicians who treat skin cancers. With unmatched access to managing international experts in the field, this program will enable participants to apply the latest research to enhance their clinical practice. Dynamic and interactive Medical Crossfire® discussions will allow experts to debate today’s key questions in the field and contribute evidence-based answers to attendees to improve their management of patients with melanoma and other cutaneous malignancies.

Benefits of Attending:
• Communicate with top experts in the field of cutaneous malignancies
• Evolve action plans to improve the treatment of your patients with skin-related cancers
• Determine the newest best practices for managing adverse events of current and novel therapies used to treat melanoma and other cutaneous tumors
• Network with colleagues and peers

Objectives:
At the conclusion of this symposium, you should be better prepared to:
• Examine the use of biomarkers in personalized care for patients with cutaneous malignancies
• Evaluate the most advanced clinical trial on current and emerging treatment options for melanoma and other skin-related tumors
• Promote optimal management protocols for the treatment of melanoma, basal cell carcinoma, squamous cell carcinoma, and other cutaneous malignancies
• Outline best practices for the prevention and mitigation of treatment-associated adverse events in the management of cutaneous malignancies